Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Access and Use of Device-Aided Therapies for Parkinson's Disease in Denmark

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Deep Brain Stimulation in Parkinson's Disease: Still Effective After More Than 8 Years

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. High-Dose Glucagon Has Hemodynamic Effects Regardless of Cardiac Beta-Adrenoceptor Blockade: A Randomized Clinical Trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Active chlordiazepoxide metabolites in a patient needing life support after treatment of alcohol abstinence

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Smartphone App to Self-Monitor Nausea During Pediatric Chemotherapy Treatment: User-Centered Design Process

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Midazolam Pharmacokinetics in Obese and Non-obese Children and Adolescents

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Background: In Denmark's five regions, there is potential inequality in access to device-aided therapy (DAT) for Parkinson's disease (PD) based on structural or socioeconomic factors. It is unclear how long DAT is maintained and affects concomitant medication.

Objectives: To investigate access to DAT by comparing the proportion of patients with DBS, subcutaneous apomorphine infusion (SCAI), or levodopa/carbidopa intestinal gel (LCIG) in Danish regions 2008-2016 and describe demographics of patients, changes in use of comedication, and maintenance of DAT.

Methods: This work is a retrospective nationwide population-based registry analysis generated by combining various registries and statistics in Denmark.

Results: From 2008 to 2016, 612 patients started DAT. There were statistically significant differences in the number of patients starting DAT between the Capital Region (99.5 per 1,000) and both Central Jutland (66.6 per 1,000) and North Jutland (70.6 per 1,000; P < 0.05). Among DBS and LCIG patients, respectively, 4% and 42% were aged ≥70 years, 68% and 63% were men (vs. 59% in the general PD population; P < 0.05 for DBS), 73% and 63% had a partner (vs. 62% in the general PD population), and 73% and 71% had a qualifying education (vs. 63% in the general PD population; P < 0.05). Use of PD-related medication decreased significantly from 4 years before to 4 years after DAT. Eighty-one percent of the patients who started LCIG, alive 4 years later, had maintained this treatment.

Conclusions: There is unequal access to DAT in the Danish regions, and political and social considerations are warranted to address structural and socioeconomic causes.

OriginalsprogEngelsk
TidsskriftMovement disorders clinical practice
Vol/bind7
Udgave nummer6
Sider (fra-til)656-663
Antal sider8
ISSN2330-1619
DOI
StatusUdgivet - aug. 2020

Bibliografisk note

© 2020 International Parkinson and Movement Disorder Society.

ID: 61311014